Lederhose Disease (Plantar Fibromatosis)

What is Lederhose Disease?

Lederhose disease, also called plantar fibromatosis or Morbus Ledderhose, is a benign but locally infiltrative fibroproliferative disorder of the plantar aponeurosis. Firm, slow-growing nodules form within the fascia, most often along the medial border of the central band. It is named after Georg Ledderhose, the German surgeon who described it in the late 19th century. According to PubMed, recent reviews emphasise that it is rare, benign, and often difficult to treat because of its tendency to recur after surgery.

It is one of the superficial fibromatoses, a family that also includes:

• Dupuytren's disease - palmar and digital fascia of the hand
• Peyronie's disease - tunica albuginea of the penis
• Knuckle pads (Garrod's nodes) - dorsal PIP joints

Because the underlying biology (myofibroblast proliferation, excess collagen) is shared, these conditions frequently coexist. The presence of one should prompt examination for the others.

Key Terminology

Epidemiology (Global)

Plantar fibromatosis is uncommon and its true incidence is poorly defined. According to PubMed, a Dutch population study estimated only about 1.2 operations for plantar fibromatosis per 100,000 people per year, underlining how rarely it reaches surgery. It is generally reported in middle-aged and older adults, with a male predominance, and bilateral involvement occurs in a significant minority. A strong link with Dupuytren's disease is consistently reported across case series and reviews.

The Disease Process

The core abnormality is uncontrolled proliferation of myofibroblasts within the plantar aponeurosis, with deposition of disorganised collagen. As in Dupuytren's disease, the process is often described in three overlapping phases:

Why the Foot Behaves Differently from the Hand

A high-yield exam concept is that, although the biology is shared with Dupuytren's, the clinical behaviour differs:

• Plantar disease tends to remain nodular, whereas palmar disease forms contracting cords.
• Toe contractures are rare because the digital extensions of the plantar fascia and the toe anatomy resist the same contracting deformity seen in fingers.
• Nodules sit on the non-weight-bearing instep, so they may be present a long time before they hurt.

Relevant Anatomy

History

Patients typically describe a firm lump in the instep of the foot, often present for months to years. Pain is variable and frequently provoked by:

• Direct pressure from shoes
• Prolonged standing and the push-off phase of gait
• Walking on hard surfaces

A history of fibromatosis elsewhere (Dupuytren's in particular) is an important clue and should be actively sought, along with risk associations such as diabetes, alcohol use, anticonvulsant therapy, and liver disease.

Examination

View larger

View larger

Imaging Pathway

According to PubMed, ultrasound is the first-line investigation and is usually sufficient to confirm the diagnosis, while MRI is reserved for aggressive, recurrent, or atypical lesions and to exclude a sarcoma.

Imaging Features

Histology

Excised tissue shows bland fibroblastic and myofibroblastic proliferation with abundant collagen and a low mitotic rate. There is no cellular atypia or necrosis, confirming the benign nature and distinguishing it from sarcoma.

View larger

Principles

The two governing principles are: start conservatively, and if you must operate, excise widely. Most patients never need surgery, and surgery itself carries a meaningful recurrence and wound-complication burden.

Disease-Related

Treatment-Related

Why Examiners Like This Topic

Lederhose disease is a favourite discriminator topic because it tests whether you understand the superficial fibromatosis family as a whole. A strong candidate links it to Dupuytren's and Peyronie's, knows the medial central band location, states that toe contractures are rare, applies a conservative-first philosophy, and explains why wide excision is needed when surgery is unavoidable.

Practical Take-Home Points

Evidence and Practice Synthesis

There are no large randomised trials or dedicated international guidelines for plantar fibromatosis given its rarity; practice is guided by case series, narrative reviews, and extrapolation from Dupuytren's disease. The globally consistent themes are summarised below.

Global Epidemiology Notes

• Population data are sparse; a Netherlands study estimated roughly 1.2 plantar fibromatosis operations per 100,000 people per year, reflecting how rarely the condition reaches surgery.
• The condition is reported worldwide across all regions, predominantly in middle-aged and older adults with a male predominance and a strong association with Dupuytren's disease.

Resource-Setting Variation

In settings with ready access to orthotic services, the conservative-first pathway is straightforward. Where custom orthoses are less accessible, simple footwear modification and padding remain effective and low-cost. Radiotherapy and sarcoma multidisciplinary pathways are concentrated in specialist centres, so referral may be required for aggressive, recurrent, or atypical disease.

The topic teaches low T2 signal as the rule and separately describes the proliferative-involutional-residual phases, but never links the MRI signal to the phase - which is why an early nodule can look worrying.

• Mature (residual) lesions are dark. A collagen-rich, hypocellular nodule is low signal on both T1 and T2 and enhances little - the 'classic' fibrous appearance.
• Early (proliferative) lesions are brighter. A cellular, actively proliferating nodule has more cells and water, so it shows higher T2 signal and avid contrast enhancement - and can mimic a more aggressive soft-tissue tumour.
• Why it matters. The signal therefore tracks the disease phase, and this overlap with sarcoma on early cellular lesions is exactly why an atypical mass needs histological confirmation rather than being assumed benign.

The management lists radiotherapy, collagenase, verapamil, tamoxifen, imatinib and shockwave but never explains why they work or why the disease phase matters.

• Radiotherapy targets proliferating cells. Low-dose radiotherapy damages the actively proliferating (myo)fibroblasts of the early/proliferative phase, so it is used for early or recurrent disease and as a post-operative adjuvant to lower recurrence; it does little for a mature, acellular residual nodule and carries skin/functional morbidity - hence selective use.
• The medical agents hit the same biology. Collagenase enzymatically lyses collagen; verapamil reduces collagen synthesis and increases collagenase; tamoxifen lowers TGF-beta-driven myofibroblast activity; imatinib inhibits fibroblast tyrosine-kinase signalling; and intralesional corticosteroid is anti-proliferative - but the evidence for all is limited, so they remain adjuncts.
• The unifying principle. All of these work best on active, proliferative disease; once the nodule is mature collagen, only excision removes it - which is why treatment is staged from conservative and biological measures early to wide fasciectomy for established, refractory disease.